Fiche publication
Date publication
octobre 2015
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BEAUCHESNE Patrick
,
Dr BERNIER-CHASTAGNER Valérie
,
Pr FAURE Gilbert
,
Pr NOEL Georges
,
Dr QUETIN Philippe
Tous les auteurs :
Beauchesne P, Quillien V, Faure G, Bernier V, Noel G, Quetin P, Gorlia T, Carnin C, Pedeux R
Lien Pubmed
Résumé
We report on a phase II clinical trial to determine the effect of a concurrent ultra-fractionated radiotherapy and temozolomide treatment in inoperable glioblastoma patients. A phase II study opened; patients over 18 years of age who were able to give informed consent and had histologically proven, newly diagnosed inoperable diagnosed and supratentorial glioblastoma were eligible. Three doses of 0.75 Gy spaced apart by at least four hours were delivered daily, five days a week for six consecutive weeks for a total of 67.5Gy. Chemotherapy was administered during the same period, which consisted of temozolomide given at a dose of 75 mg/m2, for seven days a week. After a four-week break, chemotherapy was resumed for up to six cycles of adjuvant temozolomide treatment, given every 28 days, according to the standard five-day regimen. Tolerance and toxicity were the primary endpoints; survival and progression-free survival were the secondary endpoints. In total 40 patients were enrolled in this study, 31 men and 9 women. The median age was 58 years, and the median Karnofsky performance status was 80. The concomitant ultra fractionated radiotherapy and temozolomide treatment was well tolerated. Complete responses were seen in four patients, and partial responses were reported in seven patients. The median survival from the initial diagnosis was 16 months. Several long-term survivors were noted. Concurrent ultra-fractionated radiation therapy and temozolomide treatment is well accepted by the patients. The results showed encouraging survival rates for these unfavorable patients. This article is protected by copyright. All rights reserved.
Référence
Int J Cancer. 2015 Oct 26
